Will end the year with 25% growth: Thyrocare

Thyrocare Technologies posted a good set of earnings in Q2 with margins providing the big support. In an interview with CNBC-TV18, A Velumani, Chairman, CEO and Managing Director of the company spoke about the results and his outlook for the company.

Q2FY18 was not a good quarter for the company because the quarter ended in September had Diwali and Dussehra. Normally these festivals occur in Q3 and not in Q2, he said.

We will be ending the year somewhere around 25 percent year-on-year (Y-o-Y), he added.

On price regulation issue, he said, it is too late. We should have regulated prices at least wherever it can be done much long back.

According to him, price regulation is mandatory at least in another 24 months for vast majority of the diagnostic services as well as some of the consumable utility and its billing.

Overbilling is not a simple game, it is a serious calculation, said Velumani.

Government should know what kind of price regulation will not hurt the players but at the same time, it will limit the greed of the players, he further mentioned.

Industry has growth of roughly about 18-20 percent, he said.

For full interview, watch accompanying video...